share_log
Reuters ·  May 9 06:30
X4 Pharmaceuticals Announces $125 Million Capital Infusion From $105 Million Sale of Priority Review Voucher and $20 Million Drawdown From Existing Loan Facility
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment